SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-262157
Filing Date
2022-10-13
Accepted
2022-10-13 16:07:34
Documents
16
Period of Report
2022-10-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d390069d8k.htm   iXBRL 8-K 32024
2 EX-1.1 d390069dex11.htm EX-1.1 221383
3 EX-5.1 d390069dex51.htm EX-5.1 11138
4 EX-99.1 d390069dex991.htm EX-99.1 9213
8 GRAPHIC g390069g1012111250729.jpg GRAPHIC 4496
  Complete submission text file 0001193125-22-262157.txt   476135

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA dice-20221012.xsd EX-101.SCH 2886
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dice-20221012_lab.xml EX-101.LAB 18740
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dice-20221012_pre.xml EX-101.PRE 11728
10 EXTRACTED XBRL INSTANCE DOCUMENT d390069d8k_htm.xml XML 3480
Mailing Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080
Business Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

IRS No.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40794 | Film No.: 221309180
SIC: 2834 Pharmaceutical Preparations